Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1]
G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, E.M. Stadlan.
Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.
Neurology., 34 (1984), pp. 939-944
[2]
B. Reisberg, S.H. Ferris, M.J. de León, T. Crook.
The global deterioration scale for assessment of primary degenerative dementia.
Am J Psychiatry., 139 (1982), pp. 1136-1139
[3]
R.C. Petersen, G.E. Smith, S.C. Waring, R.J. Ivnik, E.G. Tangalos, E. Kommen.
Mild cognitive impairment: clinical characterization and outcome.
Arch Neurol., 56 (1999), pp. 303-308
[4]
Y. Suzuki, S. Yamamoto, H. Umegaki, J. Onishi, N. Mogi, H. Fujishiro, A. Iguchi.
Smell identification test as an indicator for cognitive impairment in Alzheimer's disease.
Int J Geriatr Psychiatry., 19 (2004), pp. 727-733
[5]
D.W. Wesson, E. Levy, R.A. Nixon, D.A. Wilson.
Olfactory Dysfunction Correlates with Amyloid-beta Burden in an Alzheimer's Disease Mouse Model.
J Neurosci., 30 (2010), pp. 505-514
[6]
B. Dubois, H.H. Feldman, C. Jacova, S.T. DeKosky, P. Barberger-Gateau, J. Cummings, A. Delacourte, D. Galasko, S. Gauthier, G. Jicha.
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.
Lancet Neurol., 6 (2007), pp. 734-746
[7]
National Institute on Aging/Alzheimer's Disease Education and Referral Center. Alzheimer's Diagnostic Guidelines. Disponible en: http://www.nia.nih.gov/Alzheimers/Resources/diagnosticguidelines.htm.
[8]
C.R. Jack Jr., M.S. Albert, D.S. Knopman, G.M. McKhann, R.A. Sperling, M.C. Carrillo, et al.
Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Alzheimers Dement. 2011;, 7 (2011 Apr 21), pp. 257-262
[9]
M.P. Mesa Lampré.
Aproximación diagnóstica a la enfermedad de Alzheimer temprana.
¿De qué hablamos?. Aspectos conceptuales. Rev Esp Geriatr Gerontol., 46 (2011), pp. 33-38
[10]
A. Viloria.
La enfermedad de Alzheimer antes de la demencia.
Beneficios del diagnóstico precoz. Rev Esp Geriatr Gerontol., 46 (2011), pp. 47-54
[11]
H. Kessel.
Aspectos éticos del diagnóstico presintomático de la enfermedad de Alzheimer.
Rev Esp Geriatr Gerontol., 46 (2011), pp. 55-59
[12]
J.L. Molinuevo Guix.
Papel de los biomarcadores en el diagnóstico precoz de la enfermedad de Alzheimer.
Rev Esp Geriatr Gerontol., 46 (2011), pp. 39-41
[13]
G. De Meyer, F. Shapiro, H. Vanderstichele, E. Vanmechelen, S. Engelborghs, P.P. De Deyn, et al.
Alzheimer's Disease Neuroimaging Initiative.
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol., 67 (2010), pp. 949-956
[14]
A.S. Khachaturian, C.D. Corcoran, L.S. Mayer, P.P. Zandi, Breitner JC.
Cache County Study Investigators.
Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Arch Gen Psychiatry., 61 (2004), pp. 518-524
[15]
Royall DR. Location, location, location! Neurobiol Aging. 2007; 28:1481-2; discussion 1483. Epub 2006 Oct 20.
[16]
Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995; 16:271-8; discussion 278-84.
[17]
R.L. Buckner, J. Sepulcre, T. Talukdar, F.M. Krienen, H. Liu, T. Hedden, et al.
Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease.
J Neurosci., 29 (2009), pp. 1860-1873
[18]
E.M. Reiman, R.J. Caselli, L.S. Yun, K. Chen, D. Bandy, S. Minoshima, et al.
Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.
N Engl J Med., 334 (1996), pp. 752-758
[19]
W. Jagust, A. Gitcho, F. Sun, B. Kuczynski, D. Mungas, M. Haan.
Brain imaging evidence of preclinical Alzheimer's disease in normal aging.
Ann Neurol., 59 (2006), pp. 673-681
[20]
L.G. Apostolova, L. Mosconi, P.M. Thompson, A.E. Green, K.S. Hwang, A. Ramirez, et al.
Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal.
Neurobiol Aging. 2010l;, 31 (2008 Sep 24), pp. 1077-1088
[21]
V. Haroutunian, D.P. Purohit, D.P. Perl, D. Marin, K. Khan, M. Lantz, et al.
Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease.
Arch Neurol., 56 (1999), pp. 713-718
[22]
D.R. Royall, R. Palmer, A.R. Mulroy, M.J. Polk, G.C. Román, J.P. David, et al.
Pathological determinants of the transition to clinical dementia in Alzheimer's disease.
Exp Aging Res., 28 (2002), pp. 143-162
[23]
L. Olson, C. Humpel.
Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer's disease and mild cognitive impairment.
Exp Gerontol. 2010;, 45 (2009 Oct 22), pp. 41-46
[24]
M. Barandiarán.
Neuropsicología y diagnóstico temprano.
Rev Esp Geriatr Gerontol., (2011), pp. 46
[25]
H. Brodaty, M.M.B. Breteler, S.T. DeKosky, P. Dorenlot, L. Fratiglioni, C. Hock, et al.
The World of Dementia Beyond 2020.
J Am Geriatr Soc., 59 (2011), pp. 923-927
[26]
A. Viswanathan, W.A. Rocca, C. Tzourio.
Vascular risk factors and dementia: how to move forward?.
Neurology., 72 (2009), pp. 368-374
Copyright © 2011. SEGG
